Objectives
          •To develop new drugs in collaboration with Pharmaceutical Industry.

Project: 1
A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus Cyclophosphamide, Vincristine and Prednisone vs. MabThera® plus Cyclophosphamide, Vincristine, Prednisone, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma.

Sponsors: -  Hexal AG, a Sandoz Company
Principal Investigator: -  Dr. Kalyan Kusum Mukherjee

Co-Investigators: -  Dr. Suparna Mazumder

                                     Dr. Indranil Ghosh

                                     Dr. Partha Nath

                                     Dr. Durga Prasad Nanda


Chief Study Co-ordinator:   Subhabrata Dey

Study Co-ordinators:           Somnath Chakraborty

Phlebotomist:                        Surya Kanta Roy

Status: Ongoing.   

No. of Patient Recruited:   2

No. of Patient Screened Failure:   2


Project: 2
“A Multicenter, Open-Label, Randomized, Phase-II Study to Evaluate the Efficacy and Safety of NKTR 102 (PEG- Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Patients with Metastatic Colorectal Cancer (mCRC)” (Study Code: 08-PIR-03).

Sponsors:          NEKTAR Therapeutics Ltd.
                                       201 Industrial Road.
                                       San Carlos, CA 94070, USA.

Principal Investigator:   Dr. Kalyan Kusum Mukherjee

Co-Investigators:           Dr. Partha Nath

                                            Dr. Durga Prasad Nanda

Chief Study Co-ordinator:  Subhabrata Dey

Study Co-ordinators:          Somnath Chakraborty

                                                 Moumita Banerjee

Phlebotomist:                        Surya Kanta Roy

Status: Ongoing.   

No. of Patient Recruited:  5

No. of Patient Screened Failure:  14

Project: 3
IN 0901 INT: “Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients)” (Study Code: IN 0901 INT).

Sponsors:                Leo Pharma, UK.

Principal Investigator:   Dr. Kalyan Kusum Mukherjee

Co-Investigators:           Dr. Indranil Ghosh

                                           Dr. Partha Nath

                                           Dr. Durga Prasad Nanda

Chief Study Co-ordinator:   Subhabrata Dey

Study Co-ordinators:           Somnath Chakraborty

                                                 Moumita Banerjee

Phlebotomist:                        Surya Kanta Roy

Status: Ongoing.   

No. of Patient Recruited:  16

No. of Patient Screened Failure:   2


Project: 4
An Open Label, Balanced, Randomized, Multicentre, Multiple-Dose, Two-Period, Two-Treatment, Two-Sequence, Steady State, Crossover Comparative Bioequivalence Study of Two Formulations of 6 - Mercaptopurine in Adult Subjects with Acute Lymphoblastic Leukaemia (ALL). (Study Code: 19960001)

Sponsors:          Orion Corporation, Orion Pharma
                                       P.O. Box 425
                                       FI- 20101, Turku, Finland

Principal Investigator:   Dr. Kalyan Kusum Mukherjee

Co-Investigators:           Dr. Partha Nath

                                            Dr. Durga Prasad Nanda

Chief Study Co-ordinator:   Subhabrata Dey

Study Co-ordinator:             Somnath Chakraborty

                                                  Moumita Banerjee

Phlebotomist:                         Surya Kanta Roy

Status: Ongoing.   

No. of Patient Recruited:  0

No. of Patient Screened Failure:  1

Project: 5
An Open Label Randomized, Multiple-Dose, Parallel Study to Evaluate Efficacy and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) and Taxol® (Paclitaxel Injection Concentrate, Bristol-Myers Squibb.) in Metastatic Breast Cancer Patients after failure of prior chemotherapy. (Study Code: 113-10)

Sponsors:         Intas Pharmaceuticals Ltd.
                                     2nd Floor, Chinubhai Center, Ashram Road.
                                     Ahmedabad 380-009, Gujarat, India.

Principal Investigator:   Dr. Kalyan Kusum Mukherjee

Co-Investigators:           Dr. Partha Nath

                                            Dr. Durga Prasad Nanda

                                            Dr. Indranil Ghosh

Chief Study Co-ordinator:   Subhabrata Dey

Study Co-Ordinator:             Somnath Chakraborty

                                                  Moumita Banerjee

Phlebotomist:                         Surya Kanta Roy

Status: Ongoing.   

No. of Patient Recruited:  13

No. of Patient Screened Failure:   1

Designed & Maintained by : www.yzentech.com